Clinical Trials Browser

Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Advanced Biliary Tract Carcinoma

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Mouth Neoplasms

Adenocarcinoma

Carcinoma, Hepatocellular

Nasopharyngeal Carcinoma

Esophageal Squamous Cell Carcinoma

Endometrioid Endometrial Cancer

Carcinoma, Hepatocellular

Cervical Cancer Metastatic

Esophageal Neoplasms

Esophageal Squamour Cell Cancer

Salivary Gland Neoplasms

Biliary Tract Neoplasms

Carcinoma, Hepatocellular

Liver Neoplasms

Locally Advanced Rectal Cancer

Uterine Cervical Neoplasms, Recurrence

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Non-Small-Cell Lung

Colonic Neoplasms

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

Advanced Gastric Cancer

Gallbladder Neoplasms, Cholangiocarcinoma

Uterine Cervical Neoplasms

Cholangiocarcinoma

Advanced Triple Negative Breast Cancer

Breast Neoplasms, Triple Negative Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck

Esophageal Squamous Cell Carcinoma, Drug-Related Side Effects and Adverse Reactions

Stomach Neoplasms

BRCA-Mutated Breast Carcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Gastric Cancer Adenocarcinoma Metastatic

Liposarcoma, Sarcoma

Carcinoma, Hepatocellular

Uterine Cervical Neoplasms

Glioblastoma

Liver Neoplasms

Breast Neoplasms

Stomach Neoplasms

Carcinoma, Hepatocellular

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Liver Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Clinical Trials

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

NeoCamre-HN

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

FAD-HCC-001

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma

Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

LEAF-02

TASK-05

Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Neoadjuvant Therapy for Locally Advanced Colon Cancer

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma

SHIFT-001

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

NEOPBOSCC

Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

First-line Treatment of Advanced/unresectable DDLPS

SPRING

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)

Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)

A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

PASSION

Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients

mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer